Table 1.
Measures of immune response to one or more of the 12 melanoma peptides (Sum 12MP), and to the tetanus helper peptide (119 evaluable patients) - direct ELIspot data through day 50.
| Antigen | Group | N (N pos) | Rate (%) | Median cum. fold increase (median of positives) |
P (Chi-square for rates) |
|---|---|---|---|---|---|
| 12MP | No GM | 60 (44) | 73 % | 5.8 (11.6) | <0.001 |
| 12MP | GM-CSF | 58 (20) | 34 % | 1.0 (7.9) | |
| 12MP | 1 site | 60 (28) | 47 % | 1.7 (10.9) | 0.093 |
| 12MP | 2 sites | 58 (36) | 62 % | 3.4 (7.9) | |
| Tetanus | No GM | 61 (58) | 95 % | 35.4 (38.6) | 0.005 |
| Tetanus | GM-CSF | 57 (44) | 77 % | 10.6 (20.2) | |
| Tetanus | 1 site | 59 (53) | 90 % | 21.3 (23.5) | 0.28 |
| Tetanus | 2 sites | 59 (49) | 83 % | 14.3 (24.8) |